Profile data is unavailable for this security.
About the company
Sequana Medical NV is a Belgium-based company, which manufactures medical devices. The Company focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
- Revenue in EUR (TTM)712.17k
- Net income in EUR-32.56m
- Incorporated2018
- Employees62.00
- LocationSequana Medical NVKortrijksesteenweg 1112Sint-Denijs-WestremGENT 9052BelgiumBEL
- Phone+32 92928065
- Websitehttps://www.sequanamedical.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sareum Holdings Plc | 0.00 | -4.97m | 42.88m | 5.00 | -- | 57.29 | -- | -- | -0.0614 | -0.0614 | 0.00 | 0.0059 | 0.00 | -- | -- | 0.00 | -160.20 | -71.41 | -195.05 | -81.48 | -- | -- | -- | -19,709.24 | -- | -6.61 | 0.00 | -- | -- | -- | -46.96 | -- | -- | -- |
| Bergenbio ASA | 30.49k | -16.40m | 43.96m | 18.00 | -- | 2.75 | -- | 1,442.03 | -0.2647 | -0.2647 | 0.0002 | 0.0474 | 0.0021 | -- | -- | -- | -111.66 | -66.15 | -176.09 | -78.74 | -- | -- | -53,785.59 | -11,419.44 | -- | -- | 0.00 | -- | -9.00 | -31.43 | 36.98 | -- | -- | -- |
| Arecor Therapeutics PLC | 3.95m | -11.01m | 46.87m | 51.00 | -- | 3.04 | -- | 11.87 | -0.3108 | -0.3108 | 0.1114 | 0.4314 | 0.1805 | -- | 0.7516 | 66,254.90 | -50.32 | -- | -66.40 | -- | -- | -- | -278.81 | -- | 2.28 | -- | 0.0125 | -- | 107.51 | -- | -50.11 | -- | -- | -- |
| Enzymatica AB (publ) | 4.06m | -4.61m | 47.19m | 18.00 | -- | 6.55 | -- | 11.62 | -0.3247 | -0.3247 | 0.2866 | 0.4841 | 0.3269 | 1.38 | 6.48 | -- | -37.11 | -27.36 | -39.16 | -33.98 | 64.25 | 65.08 | -113.50 | -66.12 | -- | -23.26 | 0.2502 | -- | 4.00 | -0.6382 | 27.57 | -- | 7.02 | -- |
| AbL Diagnostics SA | 11.19m | 1.20m | 48.99m | 19.00 | 5.07 | 7.30 | 161.45 | 4.38 | 0.5997 | 0.5997 | 5.58 | 0.4165 | 1.18 | -- | 5.21 | 588,990.50 | 12.67 | 8.99 | 26.09 | 10.77 | 35.76 | 38.29 | 10.75 | 31.17 | 1.28 | -- | 0.31 | 0.00 | -- | 67.89 | 328.77 | -- | -- | -- |
| Hamlet BioPharma AB | 0.00 | -2.28m | 49.25m | 7.00 | -- | 12.67 | -- | -- | -0.207 | -0.207 | 0.00 | 0.3543 | 0.00 | -- | -- | -- | -63.29 | -83.52 | -69.05 | -107.84 | -- | -- | -- | -- | -- | -- | 0.0984 | -- | -- | -- | -18.87 | -- | 78.01 | -- |
| Sequana Medical NV | 712.17k | -32.56m | 50.20m | 62.00 | -- | -- | -- | 70.49 | -1.22 | -1.22 | 0.0266 | -0.6905 | 0.0394 | 1.99 | 9.08 | 11,486.61 | -180.28 | -170.42 | -4,305.25 | -660.97 | -586.32 | -255.63 | -4,572.45 | -3,072.27 | 0.2055 | -8.92 | -- | -- | -22.82 | -7.10 | -5.85 | -- | 79.05 | -- |
| Oncopeptides AB | 3.02m | -21.39m | 50.36m | 57.00 | -- | 6.21 | -- | 16.66 | -1.96 | -1.96 | 0.2776 | 0.4474 | 0.1129 | -- | 1.44 | 617,894.80 | -79.88 | -141.28 | -101.04 | -200.49 | 103.06 | -- | -707.30 | -2,689.06 | -- | -- | 0.7065 | -- | 321.54 | -- | 26.29 | -- | -- | -- |
| Gentian Diagnostics ASA | 12.25m | -502.35k | 50.47m | 58.00 | -- | 3.87 | 163.70 | 4.12 | -0.3783 | -0.3783 | 9.22 | 9.82 | 0.7646 | 1.85 | 6.35 | 2,452,035.00 | -3.14 | -10.76 | -3.58 | -11.86 | 50.84 | 41.46 | -4.10 | -26.99 | 4.14 | -- | 0.0555 | -- | 32.98 | 27.63 | 54.92 | -- | -4.92 | -- |
| Poltreg SA | 328.26k | -3.18m | 51.54m | 23.00 | -- | 2.51 | -- | 157.00 | -2.91 | -2.91 | 0.300 | 18.77 | 0.0112 | 51.22 | 27.43 | 61,494.50 | -10.82 | -6.51 | -12.42 | -7.35 | -811.65 | -391.38 | -968.62 | -449.24 | 3.87 | -- | 0.0856 | -- | 40.04 | -- | -588.92 | -- | 214.26 | -- |
| GeNeuro SA | 0.00 | -14.76m | 55.06m | 19.00 | -- | -- | -- | -- | -0.594 | -0.594 | 0.00 | -0.5548 | 0.00 | -- | -- | 0.00 | -165.51 | -96.43 | -356.72 | -185.61 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -20.96 | -- | -20.13 | -- |
| Pangaea Oncology SA | 4.66m | -2.70m | 56.10m | 62.00 | -- | 2.75 | -- | 12.03 | -0.0898 | -0.0898 | 0.1557 | 0.6691 | 0.1601 | 3.86 | 1.23 | 76,449.51 | -9.46 | -11.40 | -10.90 | -14.62 | 38.92 | 79.42 | -59.10 | -57.87 | 2.57 | -- | 0.1054 | -- | -5.11 | 10.75 | -322.51 | -- | -33.46 | -- |
| Cantargia AB | 0.00 | -24.04m | 56.77m | 22.00 | -- | 3.92 | -- | -- | -1.65 | -1.65 | 0.00 | 0.9186 | 0.00 | -- | -- | 0.00 | -80.18 | -55.08 | -100.27 | -61.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.69 | -- | -- | -- |
Data as of May 20 2024. Currency figures normalised to Sequana Medical NV's reporting currency: Euro EUR
0.39%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| LSP Advisory BVas of 31 Dec 2023 | 116.58k | 0.39% |
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
